You are viewing: Rest Of Europe Theranostics Market analysis
Part of: Theranostics Market (Global)

The Rest Of Europe Theranostics Market was valued at $130.2 Million in 2023 and projected to reach to $222.7 Million by 2028, representing a compound annual growth rate of 11.3%. The Rest Of Europe theranostics market is positioned for sustained growth through 2028, supported by demographic shifts toward older populations requiring sophisticated diagnostic and therapeutic interventions.

Rest Of Europe Theranostics Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe Theranostics Market Trends and Insights

  • Rest Of Europe is witnessing increased adoption of combined diagnostic and therapeutic solutions driven by aging populations and rising healthcare expenditure across the region.
  • Rest Of Europe's growth trajectory reflects strong demand for personalized medicine and advanced imaging technologies that enable simultaneous disease detection and treatment. Rest Of Europe's theranostics sector benefits from robust regulatory frameworks and established healthcare infrastructure that support innovation and clinical adoption.
  • Rest Of Europe is positioning itself as a key market for theranostic applications in oncology, cardiology, and neurology.
  • The 11.3% compound annual growth rate in Rest Of Europe underscores the region's commitment to integrating precision medicine into standard clinical practice, with healthcare providers increasingly recognizing the cost-effectiveness and clinical benefits of theranostic approaches..

Key Market Statistics

  • CAGR (2023-2028) 11.3% CAGR
  • Market Size, 2023 ~USD 130.2 Million
  • Forecast, 2028 ~USD 222.7 Million
  • Country Rest Of Europe

Rest Of Europe Theranostics Market Overview

Market Valuation Growth :

Rest Of Europe theranostics market valued at USD 130.2 million in 2023, with projected expansion to USD 222.7 million by 2028, representing a robust 11.3% CAGR over the forecast period.

Aging Population Driver :

Increasing geriatric demographics across Rest Of Europe countries are accelerating demand for integrated diagnostic-therapeutic solutions that enable early disease detection and targeted treatment protocols.

Healthcare Expenditure Surge :

Rising healthcare budgets and government investments in advanced medical technologies across Rest Of Europe nations are facilitating adoption of theranostic platforms in clinical settings.

Regional Adoption Momentum :

Rest Of Europe demonstrates steady market expansion driven by growing awareness of personalized medicine benefits and increasing availability of theranostic solutions in regional healthcare systems.

Rest Of Europe Theranostics Market Dynamics

  • Healthcare providers across the region are increasingly recognizing the clinical and economic value of combined theranostic approaches that reduce treatment cycles and improve patient outcomes.
  • Regulatory frameworks are gradually aligning with advanced diagnostic standards, facilitating market entry for innovative solutions. Investment in healthcare infrastructure and rising per-capita healthcare spending across Rest Of Europe countries will continue to drive market expansion.
  • The region's focus on precision medicine adoption and integration of theranostic technologies into standard clinical protocols presents significant growth opportunities.
  • Collaboration between regional healthcare institutions and international theranostics manufacturers is expected to accelerate market penetration and technology accessibility..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Rest Of Europe's theranostics market is valued at USD 130.2 million in 2023 and is forecast to reach USD 222.7 million by 2028, representing an 11.3% CAGR.
    • Rest Of Europe demonstrates strong demand for personalized medicine solutions, with theranostics gaining traction in oncology, cardiology, and neurology applications.
    • Rest Of Europe benefits from established healthcare infrastructure and supportive regulatory environments that facilitate adoption of combined diagnostic-therapeutic technologies.
    • Rest Of Europe's aging population and rising healthcare expenditure are key drivers accelerating the integration of theranostic approaches into clinical practice.

    Theranostics Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment THERANOSTICS CENTERS (End User)
    Forecast Period 2023-2028
    Growth Rate CAGR of 15.5% from 2023 to 2028
    Largest Segment RADIOPHARMACEUTICALS (Product)
    Market Size Base Year (Billions) ~USD 2.09 (2023)
    Revenue Forecast (Billions) ~USD 4.3 (2028)
    Segments Covered Product, Type, Application, End User

    Rest Of Europe Theranostics Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Diagnostic Imaging
    • Ivd/Biomarker Screening
    • Radiopharmaceuticals
    • Software & Services

    By Type

    • Iodine-131
    • Lutetium-177
    • Other Radiopharmaceuticals
    • Radium-223
    • Samarium-153
    • Yttrium-90

    By Application

    • Bone Metastasis
    • Other Applications
    • Other Cancer
    • Other Cancers
    • Prostate Cancer

    By End User

    • Hospitals And Cancer Care Centers
    • Research And Academic Centers
    • Theranostics Centers

    Target Audience

    • Theranostics Manufacturers : Companies developing diagnostic-therapeutic solutions need Rest Of Europe-specific market data to identify regional demand patterns, optimize product positioning, and plan manufacturing or distribution investments.
    • Healthcare Investors : Investment firms and venture capitalists require detailed Rest Of Europe market forecasts to evaluate portfolio opportunities, assess regional growth potential, and make informed funding decisions in precision medicine.
    • Regional Healthcare Providers : Hospitals, diagnostic centers, and healthcare networks across Rest Of Europe need market insights to justify theranostics technology adoption, budget planning, and integration into clinical workflows.
    • Medical Device Distributors : Distribution and logistics companies require Rest Of Europe market intelligence to identify growth regions, forecast demand volumes, and optimize supply chain strategies for theranostic products.
    • Healthcare Policy Makers : Government health agencies and regulatory bodies in Rest Of Europe need market data to inform reimbursement policies, technology adoption guidelines, and healthcare infrastructure development priorities.

    Reasons to Buy this Report

    • Regional Market Sizing : Obtain precise valuation data specific to Rest Of Europe theranostics market with detailed 2023-2028 projections, enabling accurate budget allocation and investment decisions for regional expansion strategies.
    • Growth Trajectory Analysis : Understand the 11.3% CAGR dynamics unique to Rest Of Europe, identifying key growth drivers including aging demographics and healthcare expenditure patterns that differentiate this region from global trends.
    • Competitive Positioning : Benchmark your organization's performance against Rest Of Europe market growth rates and identify market gaps, emerging opportunities, and competitive advantages specific to regional healthcare systems.
    • Strategic Market Entry : Develop informed market entry or expansion strategies for Rest Of Europe with data-driven insights on regional adoption rates, healthcare infrastructure readiness, and regulatory environment maturity.
    • Investment Decision Support : Support capital allocation decisions and partnership evaluations with comprehensive Rest Of Europe market intelligence, including growth forecasts and regional healthcare spending trends through 2028.

    Frequently asked questions

    What is the current market size of theranostics in Rest Of Europe?

    Rest Of Europe's theranostics market was valued at USD 130.2 million in 2023 and is expected to grow to USD 222.7 million by 2028.

    What is the projected growth rate for Rest Of Europe's theranostics market?

    Rest Of Europe's theranostics market is projected to grow at a compound annual growth rate (CAGR) of 11.3% from 2023 to 2028.

    Which therapeutic areas are driving growth in Rest Of Europe's theranostics market?

    Rest Of Europe is experiencing significant growth in theranostic applications across oncology, cardiology, and neurology, driven by demand for personalized medicine approaches.

    What factors are supporting theranostics adoption in Rest Of Europe?

    Rest Of Europe's adoption is supported by robust regulatory frameworks, established healthcare infrastructure, aging populations, and rising healthcare expenditure that enable precision medicine integration.

    How does Rest Of Europe's theranostics market compare to global trends?

    Rest Of Europe's 11.3% CAGR reflects steady regional growth, with the market benefiting from strong healthcare systems and increasing recognition of theranostic cost-effectiveness and clinical benefits.

    RESEARCH METHODOLOGY

    The study involved four major activities in estimating the current size of the theranostics market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial theranostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as OEMs, CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the theranostics market. The primary sources from the demand side include medical CDMOs, oncologists, doctors, radiologists, technicians, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

    A breakdown of the primary respondents is provided below:

    Theranostics Market Size, and Share

    *Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Estimation Methodology

    In this report, the theranostics market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insigh ts gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

    Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

    • Generating a list of major global players operating in the theranostics market.
    • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/category)
    • Revenue mapping of major players to cover a major share of the global market share, as of 2022
    • Extrapolating the global value of the theranostics market industry

    Theranostics Market Size, and Share

    Data Triangulation

    After arriving at the overall market size from the market size estimation process explained above, the global theranostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the market was validated using top-down and bottom-up approaches.

    Market Definition

    Theranostics is a term used for diagnosis and therapy. Theranostics can be broadly defined as a combination of molecularly targeted imaging and therapy, whereas imaging helps to gain information regarding presence of targeted moleculaes on cell surface and therapy progression. Radiotheranostics involves the use of radionuclide/radiopharmaceutical that delivers targeted radiation to kill the cancerous cells and imaging modality such as positron emission tomography (PET) is used to locate the cancer.  FDA approved theranostics procedures are performed for different applications such as prostate cancer, neuroendocrine tumor, etc. These procedures are mainly performed in hospitals, cancer care centers, and  theranostics centers.

    Key Stakeholders

    • Senior Management
    • End Users
    • R&D Department
    • Finance/Procurement Department

    Objectives of the Study

    • To define, describe, and forecast the size of theranostics market based on product, application, end user, and region
    • To provide detailed information regarding the major factors influencing the growth potential of the global market (drivers, restraints, opportunities, challenges, and trends)  
    • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market.   
    • To analyze key growth opportunities in the global market for key stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of market segments and/or subsegments with respect to three major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and Rest of the World (Latin America and Middle East and Africa).
    • To profile the key players in the market and comprehensively analyze their market shares and core competencies.
    • To track and analyze the competitive developments undertaken in the global market, such as product launches; agreements; expansions; and mergers & acquisitions.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global theranostics market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Geographic Analysis

    • Further breakdown of the Rest of Europe theranostics market into Italy, Spain Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
    • Further breakdown of the Rest of Asia Pacific theranostics market into Australia, South Korea, Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries

    Get the Full Theranostics Market Report

    Full forecast, segment splits, and company analysis for all Theranostics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status